The Food and Drug Administration has warned that ibogaine carries severe health risks, including life-threatening irregular heart rhythms and potential brain toxicity.

Overview Debates Related claims Topics Sources

Patients who wear contact lenses must remove them before applying Ryzumvi eye drops and wait at least 10 minutes before reinserting the lenses

Ryzumvi is not recommended for patients with active ocular inflammation, such as iritis

To reduce the risk of eye injury or contamination, patients applying Ryzumvi must avoid touching the vial tip to the eye or any surface

The MHRA said a credit card-sized patient card is expected to be included in or on antidepressant medicine boxes to reinforce safety messages and provide resource details

Former NIMH Director Steven Hyman warned at the STAT Summit that psychiatry lacks objective biomarkers to determine which patients will benefit from psychedelic treatments.

Former NIMH Director Steven Hyman noted that functional unblinding remains a clinical trial challenge because patients recognize the subjective effects of psychedelic drugs, citing FDA's 2024 rejection of Lykos Therapeutics' MDMA therapy.

Former NIMH Director Steven Hyman questioned whether subjective psychedelic experiences are necessary for antidepressant efficacy, noting that non-hallucinogenic compounds could allow at-home prescriptions if proven effective.

The Trump administration initiative to advance government-funded ibogaine research follows calls from veterans and experts for strict safety standards on psychedelic treatments.

President Donald Trump signed an executive order in April 2026 dedicating $50 million in federal funding toward research into the psychedelic drug ibogaine.

The Department of Health and Human Services is funding early-stage clinical trials of ibogaine to treat opioid addiction and post-traumatic stress disorder through ARPA-H and NIDA.

The U.S. Food and Drug Administration has opened a public docket seeking feedback by November 20, 2026 on trial design, dose selection, patient eligibility, safety monitoring, and oversight for clinical trials of ibogaine.

Multidisciplinary Association for Psychedelic Studies co-executive director Betty Aldworth stated that solving cardiac safety challenges is the central requirement before ibogaine can responsibly reach patients.

Federal funding for ibogaine clinical trials is justified by its therapeutic potential

Public attention on ibogaine was renewed following the death of 27-year-old Presley Gerber, who had traveled to Mexico for high-dose treatment while struggling with addiction.

Due to the lack of approved medical access in the U.S., Americans are paying between $5,000 and $20,000 to travel to specialized clinics in Mexico for ibogaine treatments.

Local governments should not spend opioid settlement funds on general law enforcement expenses

The New York Times identified at least 40 clinics and wellness centers in Mexico offering ibogaine treatments, ranging from luxury operations with medical staff to informal rustic facilities.

In West Virginia, local municipal governments spent nearly half of their allocated opioid settlement funds on general law enforcement expenses in 2024 and 2025.

Opioid manufacturers and distributors agreed to pay approximately $50 billion to U.S. states and the District of Columbia between 2022 and the late 2030s, with eighty-five per cent required to fund direct opioid remediation.

President Donald Trump issued an executive order in April 2026 titled "Accelerating Medical Treatments for Serious Mental Illness," which directed federal agencies to accelerate research into psychedelic medicine.